Safe Harbor for Forward-Looking Statements and Use of Document Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions ...

Core Insights - Boston Scientific Corporation reported net sales of $5.065 billion for Q3 2025, reflecting a growth of 20.3% on a reported basis, 19.4% operationally, and 15.3% organically compared to the previous year [1][6] - The company achieved a GAAP net income of $755 million, or $0.51 per share, up from $469 million, or $0.32 per share, in the prior year, with adjusted EPS of $0.75 compared to $0.63 a year ago [1][6] Financial Performance - The net sales growth by business segment included: - Endoscopy: 9.0% organic growth - Urology: 27.5% operational growth - Neuromodulation: 8.6% operational growth - MedSurg: 15.6% operational growth - Cardiology: 23.1% operational growth - Peripheral Interventions: 15.8% operational growth [4][6] - Regional net sales growth included: - U.S.: 27.0% reported growth - EMEA: 2.6% reported growth - APAC: 17.1% reported growth - LACA: 10.4% reported growth - Emerging Markets: 11.8% reported growth [4][6] Strategic Developments - The company announced the PMDA approval in Japan for expanded labeling of the FARAPULSE™ Pulsed Field Ablation System [6] - Enrollment commenced in the AGENT DCB STANCE trial to assess the AGENT™ Drug-Coated Balloon's safety and effectiveness [6] - Boston Scientific completed the acquisition of Elutia, Inc. for the EluPro™ BioEnvelope and CanGaroo® Envelope [6] - An agreement was reached to acquire Nalu Medical, Inc., which focuses on chronic pain relief through peripheral nerve stimulation [6] Guidance - For the full year 2025, the company estimates net sales growth of approximately 20% on a reported basis and 15.5% on an organic basis [7] - For Q4 2025, the estimated net sales growth is projected to be between 14.5% and 16.5% on a reported basis and 11% to 13% on an organic basis [8]

Financial Performance - The company's reported net sales reached $5061 billion, demonstrating a 228% increase year-over-year[21] - Operational net sales grew by 216% year-over-year[14] - Organic net sales increased by 174% compared to the previous year[14] - Reported earnings per share (EPS) stood at $053, compared to $022 in Q2 2024[18] - Adjusted EPS was $075, up from $062 in Q2 2024[18] - The company's free cash flow reached $1129 million in Q2 2025, compared to $660 million in Q2 2024[35] Segment Performance - MedSurg segment reported net sales of $1716 billion, a 157% increase year-over-year[22] - Cardiovascular segment reported net sales of $3345 billion, a 268% increase year-over-year[25] - Cardiology segment net sales increased by 293% to $2647 billion[27] - Electrophysiology (EP) net sales surged by 961% to $840 million[27] Guidance - The company projects Q3 2025 reported net sales growth of 17%-19% and organic net sales growth of 12%-14%[18] - Q3 2025 reported EPS is expected to be $044-$046, with adjusted EPS of $070-$072[18] - For the full year 2025, the company anticipates reported net sales growth of 18%-19% and organic net sales growth of 14%-15%[18] - Full year 2025 reported EPS is projected to be $189-$193, with adjusted EPS of $295-$299[18]

Core Insights - Boston Scientific Corporation reported net sales of $5.061 billion for Q2 2025, representing a growth of 22.8% on a reported basis, 21.6% on an operational basis, and 17.4% on an organic basis compared to the previous year [1][7][10] - The company achieved a GAAP net income of $797 million, or $0.53 per share, compared to $324 million, or $0.22 per share, a year ago, with adjusted EPS of $0.75 compared to $0.62 a year ago [1][7][10] Financial Performance - The second quarter financial results showed significant growth across various segments, with MedSurg growing by 15.7% reported, Cardiovascular by 26.8% reported, and Urology by 28.9% reported [6][7] - The net sales growth by region included a 30.7% increase in the U.S., 6.8% in EMEA, 18.0% in APAC, and 11.6% in Emerging Markets [7][8] Strategic Developments - The company received FDA approval to expand the use of the FARAPULSE™ Pulsed Field Ablation System for treating drug refractory, symptomatic persistent atrial fibrillation [7] - Boston Scientific commenced enrollment in the ReMATCH IDE clinical trial for evaluating the FARAWAVE™ and FARAPOINT™ PFA Catheters [7] - The company completed acquisitions of Intera Oncology® Inc. and SoniVie Ltd., enhancing its product offerings in the medical device sector [7] Guidance - For the full year 2025, Boston Scientific estimates net sales growth of approximately 18% to 19% on a reported basis and 14% to 15% on an organic basis [10][11] - The company projects GAAP EPS in the range of $1.89 to $1.93 and adjusted EPS of $2.95 to $2.99 for the full year [10][11]

Core Viewpoint - Boston Scientific Corporation has received FDA approval to expand the use of the FARAPULSE Pulsed Field Ablation (PFA) System for treating drug refractory, symptomatic persistent atrial fibrillation (AF) [1][2]. Group 1: Product Approval and Impact - The FARAPULSE PFA System is now approved for pulmonary vein and posterior wall ablation in patients with persistent AF, a condition affecting an estimated 59 million people globally [1][2]. - The updated instructions for use (IFU) now include the FARAWAVE PFA Catheter and FARAWAVE NAV PFA Catheter for treating patients with persistent AF [2]. Group 2: Clinical Evidence and Trial Results - The FDA approval was supported by clinical evidence from the ADVANTAGE AF clinical trial, which met primary safety and effectiveness endpoints, showing an 85.3% symptomatic AF recurrence-free rate among 260 patients [3]. - Among physicians performing three or more procedures, the symptomatic recurrence-free rate increased to 91.4% [3]. Group 3: Future Developments - Boston Scientific anticipates obtaining CE mark and approvals in Japan and China in the coming months [4]. - The company has initiated the ReMATCH IDE clinical trial to study the safety and effectiveness of the FARAWAVE PFA Catheter in patients with persistent AF who have previously undergone ablation [4].